← Leaderboards
Nicole Franziska Steinmetz
Scripps Research Institute, The
$15,228,645
Attributed
$21,167,067
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,167,067 · 15
By mechanism
R01$15,448,002 · 7
U01$3,021,691 · 1
R21$1,714,179 · 4
R00$728,170 · 1
R03$158,500 · 1
K99$96,525 · 1
Top collaborators
- Steven Fiering16 shared
- Shaochen Chen8 shared
- Jonathan Kyle Pokorski6 shared
- Ashish Ranjan4 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Jonathan Kyle Pokorski$2,075,618
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMouse ModelImmuneRecurrencePlant VirusesTumorNanoparticleDoseBaseMolecularSuccessMalignant NeoplasmsImageInsightPeptidesProteinsTumor MicroenvironmentTumor ImmunityEngineeringToxic EffectCowpea Mosaic VirusesVirus-Like ParticleImmunotherapyPlants
Grant awards (53)
Nanotechnology-based cardiovascular vaccines$698,017
R01 · FY2025 · HL · contact PI
CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy$634,736
R01 · FY2025 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$620,922
R01 · FY2025 · CA · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles$343,474
R01 · FY2025 · CA · contact PI
CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy$619,294
R01 · FY2024 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$589,872
R01 · FY2024 · CA · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$540,293
R01 · FY2024 · CA · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles$354,119
R01 · FY2024 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$608,501
R01 · FY2023 · CA · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$560,049
R01 · FY2023 · CA · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles$365,157
R01 · FY2023 · CA · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$75,431
R01 · FY2023 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$649,918
R01 · FY2022 · CA · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$562,656
R01 · FY2022 · CA · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles$391,196
R01 · FY2022 · CA · contact PI
mRNA COVID-19 Vaccines Delivered with Plant Virus/Polymer Devices$197,500
R21 · FY2022 · AI · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$75,431
R01 · FY2022 · CA · contact PI
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.$583,253
U01 · FY2021 · CA · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$576,611
R01 · FY2021 · CA · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles.$426,217
R01 · FY2021 · CA · contact PI
mRNA COVID-19 Vaccines Delivered with Plant Virus/Polymer Devices$237,000
R21 · FY2021 · AI · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$76,970
R01 · FY2021 · CA · contact PI
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.$617,631
U01 · FY2020 · CA · contact PI
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer$592,114
R01 · FY2020 · CA · contact PI
A theranostic approach for risk stratification and intervention of deep vein thrombosis.$562,917
R01 · FY2020 · HL · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles.$425,350
R01 · FY2020 · CA · contact PI
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging.$404,991
R01 · FY2020 · CA · contact PI
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.$568,456
U01 · FY2019 · CA · contact PI
A theranostic approach for risk stratification and intervention of deep vein thrombosis.$559,042
R01 · FY2019 · HL · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles.$412,419
R01 · FY2019 · CA · contact PI
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging.$406,693
R01 · FY2019 · CA · contact PI
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.$635,587
U01 · FY2018 · CA · contact PI
A theranostic approach for risk stratification and intervention of deep vein thrombosis.$569,304
R01 · FY2018 · HL · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles.$438,466
R01 · FY2018 · CA · contact PI
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging$394,519
R01 · FY2018 · CA · contact PI
Protein/Polymer Devices for Slow-Release of Immunotherapies to Treat Ovarian Cancer$235,500
R21 · FY2018 · EB
A theranostic approach for risk stratification and intervention of deep vein thrombosis$639,594
R01 · FY2017 · HL · contact PI
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology$616,764
U01 · FY2017 · CA · contact PI
Dual-pronged nano-drug delivery using plant virus-like particles$470,066
R01 · FY2017 · CA · contact PI
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging$394,519
R01 · FY2017 · CA · contact PI
Protein/Polymer Devices for Slow-Release of Immunotherapies to Treat Ovarian Cancer$195,019
R21 · FY2017 · EB
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging$409,144
R01 · FY2016 · CA · contact PI
Detection of lethal prostate cancer with macromolecule-based, EGFL-7 targeted MR imaging approach$230,295
R21 · FY2016 · EB · contact PI
Drug Delivery to Thrombotic Cardiovascular Disease$227,805
R21 · FY2016 · HL · contact PI
Engineering 'Grapevine Virus A' filaments for nanomedical applications$79,250
R03 · FY2016 · EB · contact PI
Detection of lethal prostate cancer with macromolecule-based, EGFL-7 targeted MR imaging approach$202,880
R21 · FY2015 · EB · contact PI
Drug Delivery to Thrombotic Cardiovascular Disease$188,180
R21 · FY2015 · HL · contact PI
Engineering 'Grapevine Virus A' filaments for nanomedical applications$79,250
R03 · FY2015 · EB · contact PI
Viral nanoparticles as platforms for the design of novel targeted therapeutics$237,248
R00 · FY2012 · EB · contact PI
Viral nanoparticles as platforms for the design of novel targeted therapeutics$241,922
R00 · FY2011 · EB · contact PI
Viral nanoparticles as platforms for the design of novel targeted therapeutics$249,000
R00 · FY2010 · EB · contact PI
Viral nanoparticles as platforms for the design of novel targeted therapeutics$7,425
K99 · FY2010 · EB · contact PI
Viral nanoparticles as platforms for the design of novel targeted therapeutics$89,100
K99 · FY2009 · EB · contact PI